Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Womack

Optometrist Canton, GA Doctor of Optometry

NPI 1487693446 CMS profile 832471

1455 Riverstone Pkwy Ste 100, Suite 100, Canton, GA 30114

Open in the dashboard

General payments

$930,890

1,754 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Womack of Canton, GA is reported in the CMS Open Payments database as having received $930,890 across 1,754 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $133,842 245
2024 General $129,670 229
2023 General $156,211 269
2022 General $178,478 324
2021 General $142,530 268
2020 General $49,086 77
2019 General $141,072 342

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Womack
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to John Womack were reported at $133,842. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year John Womack Optometrist median Middle half National median
2019 $141,072 $159 $67–$371 $163
2020 $49,086 $72 $29–$165 $114
2021 $142,530 $125 $46–$292 $132
2022 $178,478 $162 $66–$374 $149
2023 $156,211 $177 $72–$406 $160
2024 $129,670 $188 $77–$427 $164
2025 $133,842 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $570,085 948 payments
  2. Bausch & Lomb, a division of Bausch Health US, LLC $328,955 644 payments
  3. CooperVision Inc. $9,963 59 payments
  4. Allergan Inc. $9,244 27 payments
  5. AbbVie, Inc. $8,341 11 payments
  6. Johnson & Johnson Vision Care, Inc. $3,188 45 payments
  7. Alcon Vision LLC $625 10 payments
  8. Sight Sciences, Inc. $219 4 payments
  9. Shire North American Group Inc $93 1 payment
  10. ABB Con-Cise Optical Group LLC $67 1 payment
  11. Other $108 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $365,600 147 payments
  2. Travel and Lodging $197,866 789 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $126,825 76 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $104,570 72 payments
  5. Consulting Fee $95,975 51 payments
  6. Food and Beverage $40,028 617 payments
  7. Education $25 2 payments
Products named General payments · program years 2019–2025
  1. INFUSE $558,330 933 payments
  2. BIOTRUE $161,499 302 payments
  3. BIOTRUE ONE DAY $146,792 299 payments
  4. ULTRA $139,491 303 payments
  5. ULTRA MULTIFOCAL TORIC $80,367 135 payments
  6. INFUSE MULTIFOCAL $49,020 73 payments
  7. MULTI-FOCAL LENS $20,494 29 payments
  8. VUITY $14,235 27 payments
  9. ZENLENS $11,946 15 payments
  10. ZEN LENS $8,799 12 payments
  11. Other $44,706 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$2,255

Medicare's payments for the services billed

Medicare patients

24

Average age 76

Services billed

35

13 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Ischemic heart disease 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $44
$44 — —
MIEBO
  • Bausch & Lomb Americas Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,754 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record